Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Ovarian epithelial cancer
Stage/Subtype:  stage IV ovarian epithelial cancer
Country:  U.S.A.
Trial Type:  Treatment
Results 1-25 of 89 for your search:
Start Over
Intraperitoneal Therapy For Ovarian Cancer With Carboplatin Trial
Status: Active
Phase: Phase III, Phase II
Type: Treatment
Age: 20 and over
Trial IDs: GOTIC-001/JGOG3019, NCI-2016-00040, UMIN000003670, NCT01506856
Phase II/III Trial of Maintenance Vigil™ for High Risk Stage III/IV Ovarian Cancer
Status: Active
Phase: Phase III, Phase II
Type: Treatment
Age: 18 and over
Trial IDs: CL-PTL-119, NCI-2015-01040, NCT02346747
A Study Comparing the Combination of Trabectedin (YONDELIS) and DOXIL/CAELYX With DOXIL/CAELYX for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CR100983, NCI-2013-01419, 2012-004808-34, ET743OVC3006, NCT01846611
Clinical Trial of Lurbinectedin (PM01183) in Platinum Resistant Ovarian Cancer Patients
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: PM1183-C-004-14, NCI-2015-01497, NCT02421588
A Study of Niraparib Maintenance Treatment in Patients With HRD-Positive Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: PR-30-5017-C, NCI-2016-00574, NCT02655016
A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: BBI608-201, NCI-2014-01566, NCT01325441
Phase I/II Study of IMMU-132 in Patients With Epithelial Cancers
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: IM-T-IMMU-132-01, NCI-2014-00136, NCT01631552
A Study of Nivolumab by Itself or Nivolumab Combined With Ipilimumab in Patients With Advanced or Metastatic Solid Tumors
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: CA209-032, NCI-2013-02337, 2013-002844-10, NCT01928394
Study of Carfilzomib With Irinotecan in Irinotecan-Sensitive Malignancies and Small Cell Lung Cancer Patients
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CRAB CTC 11-001, NCI-2014-02260, CAR-IST-553, NCI-2013-02243, NCT01941316
Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: GEN701, NCI-2014-01166, NCT02001623
Phase 1-2 Study of Onapristone in Patients With Progesterone Receptor Expressing Cancers
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: ARN-AR18-CT-101, NCI-2016-00136, NCT02052128
DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, and IDO1 Inhibitor INCB024360 in Treating Patients with Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Remission
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: I 248613, NCI-2014-00771, NCT02166905
A Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers (ECHO-204)
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: INCB 24360-204 / ECHO-204, NCI-2015-00040, INCB 24360-204, NCT02327078
A Dose Escalation and Cohort Expansion Study of Anti-CD27 (Varlilumab) and Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: CDX1127-02, NCI-2015-00273, NCT02335918
A Phase I/IIa Study of BMS-986148 in Subjects With Select Advanced Solid Tumors
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CA008-002, NCI-2015-01329, 2014-002485-70, NCT02341625
A Study of CRLX101 in Combination With Weekly Paclitaxel in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CRLX101-209, NCI-2015-01474, NCT02389985
A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and Other Solid Tumors
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: PLX108-14, NCI-2015-01614, KEYNOTE-103, NCT02452424
Methoxyamine, Cisplatin, and Pemetrexed Disodium in Treating Patients with Advanced Solid Tumors or Mesothelioma That Cannot Be Removed by Surgery or Mesothelioma That Is Refractory to Cisplatin and Pemetrexed
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: PHI-76, NCI-2015-00127, 9837, NCT02535312
Phase 1/2a Evaluation of AL3818 in Subjects With Recurrent or Metastatic Endometrial, Ovarian or Cervical Cancer (AL3818-US-001)
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: AL3818-US-001, NCI-2015-01926, NCT02558348
Olaparib and Tremelimumab in Treating BRCA1 or BRCA2 Mutation Carrier Patients with Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 to 99
Trial IDs: INST 1419, NCI-2016-00434, NCT02571725
Ruxolitinib Phosphate, Paclitaxel, and Carboplatin in Treating Patients with Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: NRG-GY007, NCI-2016-00203, NCT02713386
Safety and Efficacy of CRS-207 With Epacadostat in Platinum Resistant Ovarian, Fallopian, or Peritoneal Cancer
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: ADU-CL-11, NCI-2016-00598, NCT02575807
Durvalumab, Carboplatin, and Paclitaxel in Treating Patients with Stage III-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 2015-0900, NCI-2016-00557, NCT02726997
Start Over